These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21143152)

  • 1. Interferon alpha2 in the treatment of hematological malignancies. Status and perspectives.
    Hasselbalch HC
    Curr Drug Targets; 2011 Mar; 12(3):387-91. PubMed ID: 21143152
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical value of interferon-alpha in the treatment of malignant hematologic diseases].
    Harousseau JL
    Presse Med; 1997 May; 26(18):857-9. PubMed ID: 9207887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hematologic malignancies /pediatric malignancies-current status of molecular target therapy for hematologic cancer].
    Usui N
    Gan To Kagaku Ryoho; 2010 May; 37(5):805. PubMed ID: 20524247
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeted Therapy in Hematological Malignancies: From Basic Research to Clinical Practice.
    Ma H; Mallampati S; An G; Wang J
    Biomed Res Int; 2015; 2015():157570. PubMed ID: 26436085
    [No Abstract]   [Full Text] [Related]  

  • 5. Interferon-alpha: a clinical update.
    Rieger PT
    Cancer Pract; 1995; 3(6):356-65. PubMed ID: 15859166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EPHA3 as a novel therapeutic target in the hematological malignancies.
    Keane N; Freeman C; Swords R; Giles FJ
    Expert Rev Hematol; 2012 Jun; 5(3):325-40. PubMed ID: 22780212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cytokine therapy for hematological malignancies].
    Tojo A
    Nihon Rinsho; 2012 Apr; 70 Suppl 2():279-84. PubMed ID: 23133968
    [No Abstract]   [Full Text] [Related]  

  • 8. Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies.
    Zhu N; Xiao H; Wang LM; Fu S; Zhao C; Huang H
    Future Oncol; 2015; 11(4):659-73. PubMed ID: 25686120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hematologic malignancies/pediatric malignancies].
    Usui N
    Gan To Kagaku Ryoho; 2012 May; 39(5):731. PubMed ID: 22701898
    [No Abstract]   [Full Text] [Related]  

  • 10. MUC1 in hematological malignancies.
    Stroopinsky D; Kufe D; Avigan D
    Leuk Lymphoma; 2016 Nov; 57(11):2489-98. PubMed ID: 27347699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer associated fibroblasts in hematological malignancies.
    Raffaghello L; Vacca A; Pistoia V; Ribatti D
    Oncotarget; 2015 Feb; 6(5):2589-603. PubMed ID: 25474039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting DNA Repair Pathways in Hematological Malignancies.
    Alhmoud JF; Mustafa AG; Malki MI
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33036137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms and clinical prospects of Notch inhibitors in the therapy of hematological malignancies.
    Nefedova Y; Gabrilovich D
    Drug Resist Updat; 2008 Dec; 11(6):210-8. PubMed ID: 18951834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A role of new molecular-target drugs for hematologic malignancies].
    Usui N
    Gan To Kagaku Ryoho; 2015 May; 42(5):548-9. PubMed ID: 26054087
    [No Abstract]   [Full Text] [Related]  

  • 15. New and emerging drug targets for the treatment of hematological malignancies.
    Bendall LJ
    Curr Drug Targets; 2010 Jul; 11(7):767-8. PubMed ID: 20370651
    [No Abstract]   [Full Text] [Related]  

  • 16. New perspectives in the treatment of hematological malignancies.
    Kizaki M
    Curr Pharm Biotechnol; 2006 Oct; 7(5):313. PubMed ID: 17076646
    [No Abstract]   [Full Text] [Related]  

  • 17. New targets for hematologic malignancies.
    Bradner J
    Clin Adv Hematol Oncol; 2013 Jun; 11(6):375-6. PubMed ID: 24472807
    [No Abstract]   [Full Text] [Related]  

  • 18. Targeting regulated cell death (RCD) in hematological malignancies: Recent advances and therapeutic potential.
    Zhang Y; Zhou X
    Biomed Pharmacother; 2024 Jun; 175():116667. PubMed ID: 38703504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug resistance in hematologic malignancies.
    Dalton W
    Clin Adv Hematol Oncol; 2005 Apr; 3(4):267-8. PubMed ID: 16166998
    [No Abstract]   [Full Text] [Related]  

  • 20. Emerging targets for hematological malignancies.
    Cilloni D; Frassoni F; Saglio G
    Curr Opin Drug Discov Devel; 2010 Sep; 13(5):548-58. PubMed ID: 20812146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.